Navigation Links
Boston Scientific PROMUS(R) and First-Generation TAXUS(R) Express(R) Stents Continue Excellent Performance in SPIRIT III Trial

NATICK, Mass. and SAN FRANCISCO, Sept. 21 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX) today welcomed three-year results from the SPIRIT III clinical trial, which continue to reaffirm the proven long-term safety of the Company's portfolio of drug-eluting stents, including the first-generation TAXUS((R)) Express(2)(TM) Paclitaxel-Eluting Coronary Stent System and the XIENCE V(TM) (PROMUS((R))) Everolimus-Eluting Coronary Stent System. The results were presented at the Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium in San Francisco by Gregg W. Stone, M.D., Professor of Medicine and the Director of Research and Education at the Center for Interventional Vascular Therapy at the Columbia University Medical Center/New York-Presbyterian Hospital, and Principal Investigator of the trial.

"We are very pleased that our first-generation TAXUS Express Stent continued to perform well against our PROMUS Stent in the SPIRIT III trial at three years," said Donald S. Baim, M.D., Chief Medical and Scientific Officer of Boston Scientific. "The strong outcomes among diabetic patients were particularly impressive."

The results demonstrated that the XIENCE V (PROMUS) and TAXUS Express Stents had comparable safety outcomes through three years, with equivalent rates of cardiac death (1.4% versus 1.6%, p=0.68) and low and equivalent rates of stent thrombosis using the ARC (Academic Research Consortium) definite/probable definition (1.2% and 1.6%, p=0.67). No additional stent thromboses were reported between years two and three for either stent group.

The three-year rate of Ischemia-Driven Target Lesion Revascularization (TLR) was lower for the XIENCE V (PROMUS) Stent as compared to the TAXUS Express Stent (5.4% versus 8.9%, p=0.05), contributing to a benefit for XIENCE V (PROMUS) over the TAXUS Express Stent in the composite endpoints of Major Adverse Cardiac Events (MACE, a composite endpoint of Cardiac Death, Myocardial Infarction (MI) and TLR) (9.1% versus 15.7%, p=0.003) and Target Vessel Failure (TVF, a composite endpoint of Cardiac Death, MI and Ischemia-Drive Target Vessel Revascularization) (13.5% versus 19.2%, p=0.03).

The SPIRIT III results exhibited similar rates of safety and efficacy for the XIENCE V (PROMUS) and TAXUS Express Stents in diabetic patients, with TLR rates of 5.2% versus 4.8% and MACE rates of 10.3% versus 9.4%. The rate of TLR for TAXUS Express diabetic patients was 4.8 percent as compared to 10.5 percent in non-diabetic TAXUS Express patients.

"It is noteworthy that the rate of TLR - which was equivalent for PROMUS and TAXUS Express in diabetic patients - was actually lower in diabetic patients treated with TAXUS Express than in non-diabetics treated with TAXUS Express," added Dr. Baim.

The PROMUS Stent is a private-labeled XIENCE V Everolimus-Eluting Coronary Stent System manufactured by Abbott and distributed by Boston Scientific. SPIRIT III is sponsored by Abbott. TAXUS, TAXUS Express2, Express and PROMUS are trademarks of Boston Scientific Corporation or its affiliates. XIENCE is a trademark of Abbott Laboratories Group of Companies.

The safety and effectiveness of the TAXUS Express Stent has not been established in diabetic patients.

Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit:

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "intend" and similar words. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding clinical trials, regulatory approvals, product performance and competitive offerings. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.

Factors that may cause such differences include, among other things: future economic, competitive, reimbursement and regulatory conditions; new product introductions; demographic trends; intellectual property; litigation; financial market conditions; and, future business decisions made by us and our competitors. All of these factors are difficult or impossible to predict accurately and many of them are beyond our control. For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A- Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A - Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file thereafter. We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements. This cautionary statement is applicable to all forward-looking statements contained in this document.

    CONTACT:  Paul Donovan
              508-650-8541 (office)
              508-667-5165 (cell)
              Media Relations
              Boston Scientific Corporation

              Larry Neumann
              508-650-8696 (office)
              Investor Relations
              Boston Scientific Corporation

SOURCE Boston Scientific Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Boston Micromachines Multi-DM Named One of the Years Most Innovative Products
2. Boston University School of Medicine researcher recipient of Memory Ride Grant
3. Success of Shape-Up Somerville Childhood Obesity Intervention to be Presented at the Friedman School Symposium at Tufts, October 29-31, 2007 - Boston
4. AAHFNs 2008 Annual Meeting in Boston Will Be Raising the Bar in Heart Failure Care
5. Families Invited to Celebrate Shire Day at Boston Childrens Museum
6. Boston Scientific Announces New Initiatives to Increase Shareholder Value
7. Boston Scientific Announces Additions to Clinical Sciences Organization
8. Boston University School of Medicine physician receives award from AATOD
9. Boston Scientific Announces Verdict in Cordis Litigation
10. Boston Scientific Announces Sale of Cardiac Surgery and Vascular Surgery Businesses
11. Boston Scientific and GE Healthcare Announce their First Patient Data Link to Electronic Medical Record
Post Your Comments:
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet supplements owned by ... to enhance the health of felines. The formula is all-natural and is made from ... the PawPaws Cat Kidney Support Supplement Soft Chews are Astragalus Root Extract ...
(Date:6/26/2016)... ... June 26, 2016 , ... Many women are ... with endometriosis. These women need a treatment plan to not only alleviate symptoms ... can help for preservation of fertility and ultimately achieving a pregnancy. The specialists ...
(Date:6/25/2016)... ... 25, 2016 , ... Austin residents seeking Mohs surgery services, can now turn ... to Dr. Russell Peckham for medical and surgical dermatology. , Dr. Dorsey brings specialization ... selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was under the direction ...
(Date:6/25/2016)... , ... June 25, 2016 , ... "With 30 hand-drawn ... specific project," said Christina Austin - CEO of Pixel Film Studios. , ProHand ... all within Final Cut Pro X . Simply select a ProHand generator and ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, ... and his M.D from the David Geffen School of Medicine at UCLA. He trained ... Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... -- Research and Markets has announced the addition ... - Forecast to 2022" report to their offering. ... to date financial data derived from varied research sources to ... potential impact on the market during the next five years, ... of sub markets, regional and country level analysis. The report ...
(Date:6/23/2016)... , June 23, 2016 Bracket , ... launch its next generation clinical outcomes platform, Bracket eCOA (SM) ... held on June 26 – 30, 2016 in ... first electronic Clinical Outcome Assessment product of its kind to ... #715. Bracket eCOA 6.0 is a flexible platform ...
(Date:6/23/2016)... and BOGOTA, Colombia , June 23, 2016  Astellas today announced the establishment of Astellas ... Brasil as the company,s second affiliate in Latin America . ... ... of Astellas Farma Colombia ... ...
Breaking Medicine Technology: